抗真菌药物市场规模、份额、增长分析、按药物类型、按治疗适应症、按类型、按给药途径、按分销渠道、按地区 - 行业预测，2025-2032 年

2023 年全球抗真菌药物市场规模为 149 亿美元，预计将从 2024 年的 155 亿美元增长到 2032 年的 212.1 亿美元，预测期内（2025-2032 年）的复合年增长率为 4.0%。增长%。

由于真菌感染疾病的盛行率不断上升以及对有效治疗的需求不断增加，抗真菌药物市场预计将显着增长。药物发现和开发过程的重大进展以及抗真菌研究的大量投资预计将增加市场活力。欠发达和发展中地区的新兴市场对于医疗保健提供者来说意味着丰厚的商机。然而，抗真菌抗药性和可用药物范围有限等挑战可能会长期限制市场扩张。总体而言，儘管存在潜在障碍，但不断增长的需求、技术进步和研究投资表明，未来几年研究市场的前景光明。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术进步
• 贸易分析
• 客户和购买标准分析
• 原料分析

抗真菌剂市场规模（按药物类型）

• 市场概况
• 系统性Azole和Polyenes
• 外用Azole和Polyenes
• 系统性Echinocandins和抗代谢药物
• 其他的

抗真菌剂市场规模（按治疗适应症）

• 市场概况
• 皮肤丝状菌症
• 念珠菌症
• 曲菌症
• 其他的

抗真菌剂市场规模（按类型）

• 市场概况
• 处方笺
• 场外交易（OTC）

抗霉菌剂市场规模（依给药途径）

• 市场概况
• 口服
• 局部的
• 肠外

抗真菌剂市场规模（按分销管道划分）

• 市场概况
• 医院药房
• 零售药局和药局
• 网路药局

抗真菌药物市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Abbott（USA）
• Bayer AG（Germany）
• GSK plc（UK）
• Merck & Co., Inc.（USA）
• Cadila Pharmaceuticals（India）
• Glenmark Pharmaceuticals（India）
• SCYNEXIS, Inc.（USA）
• Astellas Pharma Inc.（Japan）
• Arcadia Consumer Healthcare（USA）
• Novartis AG（Switzerland）
• Pfizer Inc.（USA）
• Leadiant Biosciences, Inc.（USA）
• Sun Pharmaceutical Industries Ltd.（India）
• Viatris Inc.（USA）
• Sanofi（France）
• Gilead Sciences, Inc.（USA）
• Apotex Inc.（Canada）
• Aurobindo Pharma Limited（India）
• Cipla Inc.（India）
• Dr. Reddy's Laboratories Ltd.（India）

结论和建议

Global Antifungal Agents Market size was valued at USD 14.9 billion in 2023 and is poised to grow from USD 15.5 billion in 2024 to USD 21.21 billion by 2032, growing at a CAGR of 4.0% during the forecast period (2025-2032).

The antifungal agents market is poised for substantial growth, driven by the rising prevalence of fungal infections and an increasing demand for effective treatments. Significant advancements in drug discovery and development processes are expected to enhance market dynamics, alongside robust investments in antifungal research. Emerging markets in underdeveloped and developing regions present lucrative opportunities for providers. However, challenges such as antifungal resistance and the limited spectrum of available agents could pose constraints on long-term market expansion. Overall, the combination of growing demand, technological advancements, and investment in research suggests a positive outlook for the antifungal agents market in the coming years, despite the potential hurdles that may arise.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antifungal Agents market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antifungal Agents Market Segmental Analysis

Global Antifungal Agents Market is segmented by Drug Type, Therapeutic Indication, Type, Route of Administration, Distribution Channel and region. Based on Drug Type, the market is segmented into Systemic Azoles & Polyenes, Topical Azoles & Polyenes, Systemic Echinocandins & Antimetabolics and Others. Based on Therapeutic Indication, the market is segmented into Dermatophytosis, Candidiasis, Aspergillosis and Others. Based on Type, the market is segmented into Prescription and Over the counter (OTC). Based on Route of Administration, the market is segmented into Oral, Topical and Parenteral. Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies & Drug Stores and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antifungal Agents Market

The global antifungal agents market is primarily driven by the rising incidence of fungal infections, which can be attributed to the widespread antibiotic resistance and the increasing prevalence of chronic infectious diseases. As more patients succumb to fungal infections due to these factors, there is an anticipated surge in the demand for antifungal agents. This escalation highlights the critical need for effective treatments to combat these infections, further propelling the market's growth. With healthcare providers seeking reliable solutions, the antifungal agents market is poised for significant expansion in response to these pressing health challenges.

Restraints in the Global Antifungal Agents Market

The global antifungal agents market faces significant limitations due to the rising phenomenon of antifungal resistance. As fungal pathogens evolve and become increasingly resistant to commonly prescribed antifungal treatments, the effectiveness of these agents diminishes, leading to a concerning epidemic of resistance. This situation poses a serious threat to the market's growth potential, as many antifungal medications may become ineffective in treating infections, ultimately impacting clinical outcomes and increasing the burden on healthcare systems. If left unaddressed, this growing challenge could hinder innovation and development of new antifungal treatments, thereby stalling market expansion in the foreseeable future.

Market Trends of the Global Antifungal Agents Market

The Global Antifungal Agents market is witnessing a notable trend towards personalized medicine, with vendors increasingly partnering with biotech firms to create tailored treatments for diverse fungal infections. By leveraging advancements in personalized approaches, such as precision diagnostics and targeted therapies, antifungal agents can enhance efficacy and improve patient outcomes. This collaboration not only addresses the unique genetic and clinical profiles of patients but also offers lucrative revenue opportunities for companies willing to innovate. As awareness of personalized medicine grows, stakeholders in the antifungal sector are positioned to capitalize on this trend, driving market growth and elevating treatment standards globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement
• Trade Analysis
• Customer & Buying Criteria Analysis
• Raw Material Analysis

Global Antifungal Agents Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Systemic Azoles & Polyenes
• Topical Azoles & Polyenes
• Systemic Echinocandins & Antimetabolics
• Others

Global Antifungal Agents Market Size by Therapeutic Indication & CAGR (2025-2032)

• Market Overview
• Dermatophytosis
• Candidiasis
• Aspergillosis
• Others

Global Antifungal Agents Market Size by Type & CAGR (2025-2032)

• Market Overview
• Prescription
• Over the counter (OTC)

Global Antifungal Agents Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Topical
• Parenteral

Global Antifungal Agents Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospitals Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies

Global Antifungal Agents Market Size & CAGR (2025-2032)

• North America (Drug Type, Therapeutic Indication, Type, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Therapeutic Indication, Type, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Therapeutic Indication, Type, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Therapeutic Indication, Type, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Therapeutic Indication, Type, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Abbott (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cadila Pharmaceuticals (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SCYNEXIS, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arcadia Consumer Healthcare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leadiant Biosciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apotex Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations